Downregulated hypothalamic 5-HT3 receptor expression and enhanced 5-HT3 receptor antagonist-mediated improvement in fatigue-like behaviour in cholestatic rats

Neurogastroenterology and Motility

Volumn 20, Issue 3, 2008, Pages 228-235

  Nguyen, H ^a   Wang, H ^b   Le, T ^a   Ho, W ^a   Sharkey, K A ^a   Swain, M G ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cholestasis; Fatigue; Receptor; Serotonin

Indexed keywords

SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SODIUM CHLORIDE; TROPISETRON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BILIARY TRACT SURGERY; CHOLESTASIS; CONTROLLED STUDY; DOWN REGULATION; FATIGUE; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; LOCOMOTION; MALE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ALANINE TRANSAMINASE; ANIMALS; BILIRUBIN; BLOTTING, WESTERN; CHOLESTASIS; DOWN-REGULATION; FATIGUE; HYDROXYINDOLEACETIC ACID; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; INDOLES; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN, 5-HT3; RNA, MESSENGER; SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 38849125468     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2007.01016.x     Document Type: Article

References (45)

1. Witt-Sullivan H, Heathcote J, Cauch K et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990 12 : 98 105.
2. Younossi ZM, Kiwi ML, Bopari N, Price LL, Guyatt G. Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol 2000 95 : 497 502.
3. Huet PM, Deslauriers J, Tran A, Faucher C, Charbonneau J. Impact of fatigue on the quality of life in patients with primary biliary cirrhosis. Am J Gastroenterol 2000 95 : 760 7.
4. Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ. Fatigue in primary biliary cirrhosis. Gut 1998 43 : 705 10.
5. Jalan R, Gibson H, Lombard MG. Patients with PBC have central but no peripheral fatigue. Hepatology 1996 24 : A162.
6. Celik T, Goren MZ, Cinar K et al. Fatigue in cholestasis and the serotenergic neurotransmitter system in the rat. Hepatology 2005 41 : 731 7.
7. Swain MG. Fatigue in chronic disease. Clin Sci 2000 99 : 1 8.
8. Jones EA, Yurdaydin C. Is fatigue associated with cholestasis mediated by altered central neurotransmission? Hepatology 1997 25 : 492 4.
9. Swain MG, Maric M. Improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment. Hepatology 1997 25 : 291 4.
10. Bailey SP, Davis JM, Ahlborn EN. Neuroendocrine and substrate responses to altered brain 5HT activity during prolonged exercise to fatigue. J Appl Physiol 1993 77 : 3006 12.
11. Wilson WM, Maughan RJ. Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5HT reuptake inhibitor reduces the capacity to perform prolonged exercise. Exp Physiol 1992 77 : 921 4.
12. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002 71 : 533 54.
13. 3 receptor antagonists-preliminary results. Scand J Rheumatol 2000 2a (Suppl. 113 72 7.
14. 3 serotonin antagonist: a pilot study. Clin Rheumatol 2000 19 : 6 8.
15. Piche T, Vanbiervliet G, Cherikh F et al. Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomized, double-blind, placebo controlled study. Gut 2005 54 : 1169 73.
16. Theal JL, Toosi MN, Girlan LM et al. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology 2005 41 : 1305 12.
17. Burak KW, Le T, Swain MG. Increased sensitivity to the locomotor activating effects of corticotropin-releasing hormone in cholestatic rats. Gastroenterology 2002 122 : 681 8.
18. Sutton RE, Koob GF, LeMoal M, Rivier J, Vale W. Corticotropin-releasing factor produces behavioral activation in rats. Nature 1982 297 : 331 3.
19. Vercoulen JH, Swanink CM, Zitman FG et al. Randomized, double-blind, placebo controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996 347 : 858 61.
20. Newton JL, Gibson GJ, Tomlinson M, Wilton K, Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology 2006 44 : 91 8.
21. Cameron GR, Oakley CL. The bile duct ligated rat. J Pathol Bacteriol 1932 35 : 769 98.
22. 3 antagonist tropisetron (ICS 205-930). Psychopharmacology 1995 119 : 186 97.
23. 3 receptor antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat. Eur J Pharmacol 1993 230 : 63 8.
24. Tou JCL, Wade CE. Determinants affecting physical activity levels in animal models. Exp Biol Med 2002 227 : 587 600.
25. Swanson LW. Cerebral hemisphere regulation of motivated behavior. Brain Res 2000 886 : 113 64.
26. Lowry CA, Moore FL. Regulation of behavioral responses by corticotropin-releasing factor. Gen Comp Endocrinol 2006 146 : 19 27.
27. Swain MG, Patchev V, Vergalla J, Chrousos G, Jones EA. Suppression of hypothalamic-pituitary-adrenal axis responsiveness to stress in a rat model of acute cholestasis. J Clin Invest 1993 91 : 1903 8.
28. Spier AD, Wotherspoon G, Nayak SU, Nicholas RA, Priestly JV, Lummis SL. Antibodies against the extracellular domain of the 5-HT3 receptor label both native and recombinant receptors. Brain Res Mol Brain Res 1999 67 : 221 30.
29. 3 receptors in the rat gastrointestinal tract. Gastroenterology 2002 123 : 217 26.
30. Burak KW, Le T, Swain MG. Increased midbrain 5-HT1A receptor number and responsiveness in cholestatic rats. Brain Res 2001 892 : 376 9.
31. 3 receptor antagonists: a critical update on therapeutic potential. TIPS 1993 14 : 265 70.
32. Swain MG, Le T. Chronic cholestasis in rats induces anhedonia and a loss of social interest. Hepatology 1998 28 : 6 10.
33. van Hooft JA, Vijverberg HPM. 5HT3 receptors and neurotransmitter release in the CNS: a nerve ending story? TINS 2000 23 : 605 9.
34. 3 receptor subtype in the rat brain and spinal cord. J Comp Neurol 1998 402 : 385 401.
35. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002 53 : 865 71.
36. Bhatnager S, Sun LM, Raber J, Maren S, Julius D, Dallman MF. Changes in anxiety-related behaviors and hypothalamic-pituitary-adrenal activity in mice lacking the 5-HT3A receptor. Physiol Behav 2004 81 : 545 55.
37. 3A subunit is a major determinant of serotonin receptor function. Nature 1999 397 : 359 63.
38. Morales M, Wang SD. Differential composition of 5-hydroxytryptamine 3 receptors synthesized in the rat CNS and peripheral nervous system. J Neurosci 2002 22 : 6732 41.
39. Ilegems E, Pick HM, Deluz C, Kellenberger S, Vogel H. Non-invasive imaging of 5HT3 receptor trafficking in live cells. J Biol Chem 2004 279 : 53346 4452.
40. Farber L, Haus U, Spath M, Drechsler S. Physiology and pathophysiology of the 5-HT3 receptor. Scand J Rheumatol Suppl 2004 119 : 2 8.
41. Swain MG. Fatigue in liver disease: pathophysiology and clinical management. Can J Gastroenterol 2006 3 : 181 8.
42. Frissora CL, Kock KL. Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Rep 2005 4 : 264 71.
43. Minderhoud IM, Oldenburg B, van Dam PS, van Berge Henegouwen GP. High prevalence of fatigue in quiescent inflammatory bowel disease is not related to adrenocortical insufficiency. Am J Gastroenterol 2003 5 : 1088 93.
44. Shanahan F. Brain-gut axis and mucosal immunity: a perspective on mucosal psychoneuroimmunology. Semin Gastrointest Dis 1999 1 : 8 13.
45. Dinan TG, Quigley EMM, Ahmed SMM et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006 130 : 304 11.